One of many striking things about the US Food and Drug Administration’s 22 October approval of the first COVID-19 therapeutic is how routine the agency action is despite the unusual pressures of the times.
Gilead Sciences, Inc.’s Veklury (remdesivir) received regular approval with an NDA based on three Phase III trials with hard...